Bausch Health posted a 3 percent increase in third-quarter sales to $2,209 million. Revenues rose by 4 percent both at constant currency rates and organically. Operating income increased to $329 million from $117 million a year earlier thanks to a decrease in amortization and impairments as well as higher sales and gross margins. The net loss narrowed to $49 million from $350 million, while adjusted net income grew by 5 percent to $425 million. The Bausch + Lomb/International segment posted a 2 percent increase in sales to $1,175 million. Organic growth at constant currency rates reached 5 percent, driven by the company's global consumer, international RX and global vision care businesses. The management improved its full-year guidance and now expects revenues of $8,475-8,625 million and adjusted Ebitda of $3,500-3,600 million.